Skip to main content
Clinical Trials/CTRI/2023/06/054147
CTRI/2023/06/054147
Not Yet Recruiting
Phase 3

A randomized, double blind study to evaluate the effect of integrative approach of allopathic and Ayurvedic medications in the management of chronic stable angina

Shathyu Ayurveda Pvt Ltd0 sites0 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: I998- Other disorder of circulatory system
Sponsor
Shathyu Ayurveda Pvt Ltd
Status
Not Yet Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Shathyu Ayurveda Pvt Ltd

Eligibility Criteria

Inclusion Criteria

  • All patients with symptoms of angina and documented CAD by CTCA with or without prior evidence of CAD will be eligible to be enrolled into the study.

Exclusion Criteria

  • Patients already listed or planning to undergo coronary angioplasty in the 6 month study period
  • Pregnant women
  • Seriously ill patients
  • Patients with psychiatric illnesses

Outcomes

Primary Outcomes

Not specified

Similar Trials

Unknown
Phase 2
To see the effect of H-009 and Arsenic-sulphuricum-flavum in color change of vitiligo white patches and examining safety in patients
CTRI/2012/03/002531Homeopathy India Private Limited
Completed
Phase 3
A randomized, double-blind study to evaluate the safety and effectiveness of the Exhale Drug-eluting stent in homogeneous emphysema subjects with severe hyperinflation, the EASE - study. & Local ammendment: Protocol revision to evaluate the ExhaleUltraNeedle in the EASE study.COPDEmphysema10038716
NL-OMON30701Broncus Technologies Inc.15
Active, Not Recruiting
N/A
A randomised, double blind study to evaluate the safety and efficacy of the p38 kinase inhibitor, GW856553, in subjects with neuropathic pain from lumbosacral radiculopathy
EUCTR2009-012836-33-SEGlaxoSmithKline Research & Development Limited142
Active, Not Recruiting
N/A
A randomised, double blind study to evaluate the safety and efficacy of the p38 kinase inhibitor, GW856553, in subjects with neuropathic pain from lumbosacral radiculopathyeuropathic pain from lumbosacral radiculopathyMedDRA version: 12.0Level: LLTClassification code 10037779Term: Radiculopathy
EUCTR2009-012836-33-DEGlaxoSmithKline Research & Development Limited142
Active, Not Recruiting
Phase 1
A randomised, double blind study to evaluate the safety andefficacy of the p38 kinase inhibitor, GW856553, in subjects withneuropathic pain from peripheral nerve injury.Estudio aleatorizado, doble ciego para evaluar la seguridad y la eficacia de GW856553, un inhibidor de la quinasa p38, en sujetos con dolor neuropático por lesión de nervio periférico.europathic painMedDRA version: 9.1Level: LLTClassification code 10054095Term: Neuropathic pain
EUCTR2009-010091-17-ESGlaxoSmithKline Research & Development Limited